Last €91.74 EUR
Change Today -0.144 / -0.16%
Volume 938.0
NOTA On Other Exchanges
Symbol
Exchange
Xetra
New York
OTC US
Mexico
SIX Swiss Ex
SIX Swiss Ex
Frankfurt
As of 9:33 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

novartis ag-sponsored adr (NOTA) Snapshot

Open
€91.80
Previous Close
€91.88
Day High
€91.83
Day Low
€90.70
52 Week High
02/26/15 - €91.95
52 Week Low
03/20/14 - €57.97
Market Cap
248.3B
Average Volume 10 Days
260.9
EPS TTM
--
Shares Outstanding
2.7B
EX-Date
03/2/15
P/E TM
--
Dividend
€2.82
Dividend Yield
2.19%
Current Stock Chart for NOVARTIS AG-SPONSORED ADR (NOTA)

novartis ag-sponsored adr (NOTA) Related Businessweek News

View More BusinessWeek News

novartis ag-sponsored adr (NOTA) Details

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company’s Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

133,413 Employees
Last Reported Date: 01/27/15
Founded in 1895

novartis ag-sponsored adr (NOTA) Top Compensated Officers

Chief Executive Officer and Member of Executi...
Total Annual Compensation: SFr.6.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: SFr.2.6M
President of Institutes for Biomedical Resear...
Total Annual Compensation: $3.0M
Global Head of Novartis Business Services and...
Total Annual Compensation: SFr.1.2M
Division Head of Novartis Pharmaceuticals and...
Total Annual Compensation: $3.9M
Compensation as of Fiscal Year 2014.

novartis ag-sponsored adr (NOTA) Key Developments

Cadilla, Lupin, Cipla, Sun Pharma, Dr Reddy's, Pfizer and Sandoz Reportedly Eyes Takeover Of CLARIS Lifesciences's Injectables Business

Pfizer Limited (BSE:500680), Novartis AG (SWX:NOVN), Lupin Limited (BSE:500257), Cipla Limited (BSE:500087), Dr. Reddy's Laboratories Ltd. (BSE:500124), Sun Pharmaceutical Industries Limited (BSE:524715) and Cadila Healthcare Limited (BSE:532321) are reportedly looking to acquire the injectables business from Claris Lifesciences Limited (BSE:533288).

Novartis Seeks To Sell Assets Related To Its BRAF and MEK To Array

Novartis AG (SWX:NOVN) has announced that will sell its entire assets related to its BRAF and MEK inhibitor drugs, currently being developed, to Array BioPharma, Inc. (NasdaqGM:ARRY) to clear charges that Novartis's $16 billion deal to acquire London-based GlaxoSmithKline range of cancer-treatment drugs would likely be anticompetitive. If the acquisition moves forward as planned, Novartis is expected to postpone or end development of both its BRAF and MEK inhibitors, as well as the combination product.

Pharmacyclics Reportedly Attracted Interest For Sale

Pharmacyclics Inc. (NasdaqGS:PCYC) intends to sell itself and has attracted interest from the buyers. Johnson & Johnson (NYSE:JNJ) and Novartis AG (SWX:NOVN) have shown interest in acquiring Pharmacyclics, Bloomberg reported. Pharmacyclics could fetch $17 billion-$18 billion from a possible sale, Bloomberg said citing people familiar with the matter. Reuters added that representatives of all three companies declined to comment. Pharmacyclics shares rose 16%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NOTA:GR €91.74 EUR -0.144

NOTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $168.65 USD -0.96
Amgen Inc $157.72 USD -1.25
Bayer AG €131.62 EUR +0.108
Gilead Sciences Inc $103.53 USD -0.66
GlaxoSmithKline PLC 1,542 GBp -12.50
View Industry Companies
 

Industry Analysis

NOTA

Industry Average

Valuation NOTA Industry Range
Price/Earnings 23.9x
Price/Sales 4.6x
Price/Book 3.5x
Price/Cash Flow 27.3x
TEV/Sales 4.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.